Novo Nordisk A/S (NOVO-B.CO)
Exchange: Copenhagen Exchange
Currency: DKK
Price: 741.60 (Close)
Summary
| 52 Week range | 200d Moving Avg. | Beta |
| 413.01 – 773.70 | 651.68 | 0.31 |
| Dividend | Dividend Yield | Ex-Dividend date |
| 10.40 | 1.40% | 2022-03-25 |
| P/E Ratio | Latest EPS | DGR 3 years |
| 35.92 | 20.74 | 6.00% |
Overvalued
Low
Very low Volatility
High
Slow
Dividend Growth
Fast
Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson’s diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
| Sector: | Industry: | |
| Healthcare | Biotechnology | |
Total ESG Score
26 – 31 percentile
Environment
3 – 5 percentile
Social
15 – 5 percentile
Governance
13 – 5 percentile
Controversy level
3
MSCI ESG-Rating
n.a.
see MSCI ESG rating explained
Dividend Safety Metrics
| Latest EPS | 20.74 | |
| Annual Payout | 10.40 | |
| Payout Ratio | 50.14% | |
| Dividend growth | 22 Years | |
| Dividend Score | 71 | |
| Dividend Coverage Ratio | 1.99 | |
| Altman-Z score | 0.00 |
Novo Nordisk A/S (NOVO-B.CO) Valuation
Novo Nordisk A/S current dividend yield of 1.40% is -32% below its 5-year average. The 5-year average dividend yield is 2.06% (see red-line in chart). This indicates the stock looks overvalued today.
Novo Nordisk A/S (NOVO-B.CO) Performance
The chart below displays the total price return(%) of Novo Nordisk A/S for different periods:
Novo Nordisk A/S (NOVO-B.CO) Total Return
The chart below displays the (CAGR) total return (%) including all dividends paid of Novo Nordisk A/S for different periods:
Dividend Scorecard
| Dividend Yield (TTM) | Annual Payout | Payout Ratio | Dividend growth |
| 1.40 | 10.40 | 50.14% | 22 Years |
Dividend Growth Summary
| 3 Year Growth Rate (CAGR) | 6.00% |
| 5 Year Growth Rate (CAGR) | -0.11% |
| 10 Year Growth Rate (CAGR) | 16.68% |
Dividend Growth Rates History
| Year | Payout Amount | Annual Payout Growth (YoY) |
|---|---|---|
| 2021 | 9.350 | 8.7% |
| 2020 | 8.600 | 5.5% |
| 2019 | 8.150 | 3.8% |
| 2018 | 7.850 | 3.3% |
| 2017 | 7.600 | -19.1% |
| 2016 | 9.400 | 88.0% |
| 2015 | 5.000 | 11.1% |
| 2014 | 4.500 | 25.0% |
| 2013 | 3.600 | 28.6% |
| 2012 | 2.800 | 40.0% |
| 2011 | 2.000 | 33.3% |
| 2010 | 1.500 | 25.0% |
| 2009 | 1.200 | 33.3% |
| 2008 | 0.900 | 28.6% |
Novo Nordisk A/S (NOVO-B.CO) Dividend Payment History